Table 1.
Clinical characteristics in 184 CRPC patients adjusted by propensity score matching.
| Variables | Total (n = 184) | Abi (n = 92) | Enz (n = 92) | p Value |
|---|---|---|---|---|
| Age (mean ± SD) | 73.5 + 7.8 | 74.0 + 8.0 | 73.0 + 7.6 | 0.355 |
| SRE during follow-up | ||||
| No (%) | 144 (78.3) | 72 (78.3) | 72 (78.3) | |
| Yes (%) | 40 (21.7) | 20 (21.7) | 20 (21.7) | 1.000 |
| Taxanes during follow-up | ||||
| No (%) | 159 (86.4) | 80 (87.0) | 79 (85.9) | |
| Yes (%) | 25 (13.6) | 12 (13.0) | 13 (14.1) | 0.809 |
| ADT response duration | ||||
| ≥12months (%) | 136 (73.9) | 65 (70.6) | 71 (77.2) | |
| <12 months (%) | 48 (26.1) | 27 (29.4) | 21 (22.8) | 0.809 |
| Median PSA level at diagnosis (ng/mL) (quartile) | 124.0 (29.3, 395.6) | 124.3 (41.9, 327.1) | 93.8 (25.7, 574.8) | 0.685 |
| Median PSA level at first line treatment (ng/mL) (quartile) | 6.8 (2.3, 30.1) | 6.8 (2.0, 30.4) | 6.8 (2.5, 30.1) | 0.918 |
| Gleason sum score (%) | ||||
| ≤7 | 20 (10.9) | 9 (9.8) | 11 (12.0) | |
| 8 | 41 (22.3) | 20 (21.7) | 21 (22.8) | |
| 9 | 113 (61.4) | 56 (60.9) | 57 (62.0) | |
| 10 | 10 (5.4) | 7 (7.6) | 3 (3.3) | 0.598 |
| Local treatment prior to ADT (%) | ||||
| Non | 156 (84.8) | 77 (83.7) | 79 (85.9) | |
| Prostatectomy | 16 (8.7) | 9 (9.8) | 7 (7.6) | |
| Radiation | 8 (4.3) | 5 (5.4) | 3 (3.3) | |
| Others | 4 (2.2) | 1 (1.1) | 3 (3.3) | 0.311 |
| Initial ADT (%) | ||||
| LHRH analog + NAs | 162 (88.0) | 78 (84.8) | 84 (91.3) | |
| LHRH analog | 11 (6.0) | 7 (7.6) | 4 (4.3) | |
| NAs | 7 (3.8) | 5 (5.4) | 2 (2.2) | |
| Others | 4 (2.2) | 2 (2.2) | 2 (2.2) | 0.113 |
| Mets at first line treatment (%) | ||||
| M0 | 57 (31.0) | 27 (29.4) | 30 (32.6) | |
| M1 | 127 (69.0) | 65 (70.7) | 62 (67.4) | 0.345 |
| Visceral mets at first line treatment (%) | ||||
| No | 165 (89.7) | 82 (89.1) | 83 (90.2) | |
| Yes | 19 (10.3) | 10 (10.9) | 9 (9.8) | 0.809 |
| LN mets at first line treatment (%) | ||||
| Non | 117 (63.6) | 55 (59.8) | 62 (67.4) | |
| Regional | 45 (24.5) | 23 (25.0) | 22 (23.9) | |
| Non-regional | 22 (12.0) | 14 (15.2) | 8 (8.7) | 0.350 |
| No. of bone mets at first line treatment (%) | ||||
| 0 | 83 (45.1) | 40 (43.5) | 43 (46.7) | |
| 1 | 23 (12.5) | 11 (12.0) | 12 (13.0) | |
| 2 | 15 (8.2) | 8 (8.7) | 7 (7.6) | |
| >3 | 63 (34.2) | 33 (35.9) | 30 (32.6) | 0.948 |
| ECOG-PS (%) | ||||
| 0 | 104 (56.5) | 51 (55.4) | 53 (57.6) | |
| 1 | 66 (35.9) | 35 (38.0) | 31 (33.7) | |
| ≥2 | 14 (7.6) | 6 (6.6) | 8 (8.7) | 0.684 |
| Neutrophil-lymphocyte ratio at first line treatment (mean ± SD) | 2.99 ± 2.49 | 3.08 ± 2.93 | 2.84 ± 1.59 | 0.648 |
| Hb at first line treatment (g/dL) (mean ± SD) | 12.2 ± 1.8 | 12.1 ± 1.8 | 12.3 ± 1.8 | 0.627 |
| Platelet count at first line treatment (103/uL) (mean ± SD) | 213 ± 75 | 215 ± 80 | 210 ± 71 | 0.640 |
| ALP at first line treatment (U/L) (quartile) | 248 (202, 350) | 252 (199, 370) | 246 (213, 344) | 0.884 |
| LDH at first line treatment (U/L) (quartile) | 200 (182, 238) | 201 (177, 231) | 200 (185, 240) | 0.675 |
| Albumin (g/dL) (quartile) | 4.1 (3.8, 4.4) | 4.1 (3.6, 4.3) | 4.2 (3.9, 4.4) | 0.126 |
| CRP (mg/dL) (quartile) | 0.1 (0.05, 0.32) | 0.1 (0.05, 0.23) | 0.1 (0.05, 0.48) | 0.670 |
CRPC: castration-resistant prostate cancer, Abi: abiraterone, Enz: enzalutamide, SD: standard deviation, SRE: skeletal-related events, PSA: prostate-specific antigen, ADT: androgen deprivation therapy, LN: lymph node, Mets: metastasis, ECOG-PS: Eastern Cooperative Oncology Group performance status, Hb: hemoglobin, ALP: alkaline phosphatase, LDH: lactate dehydrogenase, CRP: C-reactive protein, LHRH: luteinizing hormone-releasing hormone, NAs: nonsteroidal antiandrogens.